


CASTELLANOS & Co.
Calle 94 A No.7A-09
Bogotá-Colombia

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 11-051428- -00002-0000

Fecha: 2011-06-20 14:51:03 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 444 RESPUESTAREQUE Folios: 31

Señor

Director de la División de Nuevas Creaciones

Superintendencia de Industria y Comercio

Ministerio de Comercio, Desarrollo Industria y Turismo

E. S. D.

Expediente No. **11.051.428**

Solicitud de Patente de Invención para: **"DERIVADOS DE ACIDO 1-AMINO-2-CICLOBUTILETILBORONICO"**

Solicitante: **MILLENNIUM PHARMACEUTICALS, INC.**

RESPUESTA A EXAMEN DE FORMA

LUIS PATIÑO LEYVA, mayor de edad, identificado y domiciliado como aparece al pie de mi firma, en atención a su oficio No. 8893 notificado el 3 de junio de 2011, atentamente me permito presentar el documento en que consta la cesión del derecho a la patente de los inventores al solicitante debidamente apostillado junto con su traducción oficial. Presento también copia del comprobante de presentación de la solicitud Estadounidense No. 12/586,650 en donde se establece que la misma reivindica prioridad de la solicitud provisional No. **61/194,614** de fecha 29 de septiembre de 2008.

Adicionalmente, presento resumen modificado de conformidad con el Artículo 31 de la Decisión 486:

"La invención se relaciona con derivados de ácido 1-amino-2-ciclobutiletílborónico útiles como inhibidores de proteasoma, y a composiciones farmacéuticas que comprenden los compuestos de la invención para el tratamiento de diferentes enfermedades de proliferación celular."



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
12/586,650	09/25/2009	1614	1220	MPI08-013PIRNM	16	1

CONFIRMATION NO. 8289

30405
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
CAMBRIDGE, MA 02139

UPDATED FILING RECEIPT



0000000039206682

DEC 17 2009

Date Mailed: 12/17/2009

BS

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please submit a written request for a Filing Receipt Correction. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections

Applicant(s)

Paul E. Fleming, Wellestey, MA; ✓
Jing Li, Lansdale, PA; ✓

Assignment For Published Patent Application

Millennium Pharmaceuticals, Inc., Cambridge, MA ✓

Power of Attorney: The patent practitioners associated with Customer Number 30405 ✓

Domestic Priority data as claimed by applicant

This appln claims benefit of 61/194,614 09/29/2008 ✓

Foreign Applications

If Required, Foreign Filing License Granted: 10/13/2009

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is US 12/586,650

Projected Publication Date: 04/01/2010 ✓

Non-Publication Request: No

Early Publication Request: No

Title

✓ Derivatives of 1-amino-2-cyclobutylethylboronic acid

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER

Title 35, United States Code, Section 184

Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as

set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. Country: United States of America

This public document

2. has been signed by T. Lawrence

3. acting in the capacity of Certifying Officer

4. bears the seal/stamp of U. S. Patent and Trademark Office

Certified

5. at Washington, D.C.


6. the eighteenth of May, 2011

7. by Assistant Authentication Officer, United States Department of State

8. No. 11038719-1

9. Seal/Stamp:

10. Signature:


Bernesia T. Crawford

A 7293572



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

**UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office**

April 29, 2011

**THIS IS TO CERTIFY THAT ANNEXED IS A TRUE COPY FROM THE
RECORDS OF THIS OFFICE OF A DOCUMENT RECORDED ON
DECEMBER 7, 2009.**

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office

T. Lawrence

**T. LAWRENCE
Certifying Officer**



31

Form PTO-1595 (Rev. 03-09)
OMB No. 0651-0027 (exp. 03/31/2009)U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark OfficeRECORDATION FORM COVER SHEET
PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

(1) Paul E. Fleming
(2) Jing LiAdditional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance/Execution Date(s):

Execution Date(s) (1): 10/22/2009; (2): 10/27/2009

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Joint Research Agreement
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other

2. Name and address of receiving party(ies)

Name: Millennium Pharmaceuticals, Inc.

Internal Address:

Street Address: 40 Landsdowne Street

City: Cambridge

State: Massachusetts

Country: USA

Zip: 02139

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

☐ This document is being filed together with a new application.

A. Patent Application No.(s)

B. Patent No.(s)

12/586,650

Additional numbers attached? ☐ Yes ☒ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Janice M. Klunder

Internal Address:

Street Address: 40 Landsdowne Street

City: Cambridge

State: Massachusetts

Zip: 02139

Phone Number: 617-551-3699

Fax Number: 617-551-8820

Email Address: janice.klunder@mpi.com

6. Total number of applications and patents involved: 1

7. Total fee (37 CFR 1.21(h) & 3.41) \$40.00


- ☒ Authorized to be charged to deposit account
☐ Enclosed
☐ None required (government interest not affecting title)

8. Payment Information

Deposit Account Number 501668

Authorized User Name Janice M. Klunder

9. Signature:



Signature

December 7, 2009

Date

Janice M. Klunder, Reg. No. 41,121

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

10

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O. Box 1450, Alexandria, V.A. 22313-1450

700424378

PATENT
REEL: 023618 FRAME: 0033

CH \$40.00 \$01668 12586650

Practitioner's Docket No. MPI08-013P1RNM**PATENT**

For: U.S. and Foreign Rights

For: U.S. Application

By: Inventors

ASSIGNMENT OF INVENTION**WHEREAS,****ASSIGNORS:**Paul E. Fleming19 Eaton Ct., Wellesley, Massachusetts 02481Nationality: United States of AmericaJing Li2223 Ayreshire Drive, Lansdale, Pennsylvania 19446Nationality: China

have co-invented a certain invention entitled:

DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID

for which they have executed an application for a United States patent, which was filed on September 25, 2009, under U.S. Application No. 12/586,650; and

WHEREAS,**ASSIGNEE:****MILLENNIUM PHARMACEUTICALS, INC.**

40 Landsdowne Street

Cambridge, Massachusetts 02139

State of Incorporation: Delaware

is desirous of acquiring ASSIGNORS' entire domestic and foreign right, title, and interest in and under the invention described in the patent application;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNORS hereby, without reservations, sell, assign and transfer to ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and to the invention in the United States and in every foreign country, and our entire right, title, and interest in and to the patent application and such other applications (e.g., provisional applications, non-provisional applications, continuations, continuations-in-part, divisionals, reissues, reexaminations, National phase applications, including petty patent applications and utility model

PATENT**REEL: 023618 FRAME: 0034** 9

Practitioner's Docket No. MPI08-013P1RNM

utility model applications) as may be filed on the invention in the United States or in any foreign country, and the patents, extensions, or derivations thereof, both foreign and domestic, that may issue thereon; said invention, applications, and patents to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made.

ASSIGNORS hereby authorize the ASSIGNEE to insert in this assignment document the filing date and application number of the application if the date and number are unavailable at the time this document is executed.

ASSIGNORS hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein. ASSIGNORS further acknowledge that this assignment carries with it the right in ASSIGNEE to claim under the Patent Cooperation Treaty, the International Convention and/or other international arrangement for any such application the date of the United States application (or any other application on the invention) to gain priority with respect to other applications.

ASSIGNORS hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNORS further covenant that we will at any time upon request, without further or additional consideration, but at the expense of the ASSIGNEE, execute and deliver such additional assignments and other writings and do such additional acts as the ASSIGNEE may deem necessary or desirable to perfect the ASSIGNEE's enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, continuation, continuation-in-part, divisional, reissued, reexamined, and National phase patents of the United States or of any and all foreign countries on the invention, and in enforcing any rights or choses in action accruing as a result of such applications or patents, and by executing statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of, the assigns and legal representative of all parties hereto.

(Page 2 of 4)

PATENT
REEL: 023618 FRAME: 0035

Practitioner's Docket No. MPI08-013P1RNM

AND, ASSIGNORS do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 22 day of October, 2009.


Signature of Inventor Paul E. Fleming


Witness 1 Signature

PAUL WENDLER
Witness 1 (Typed or Handwritten) Name

100 POWDER MILL RD
SADDURY MA 01776
Witness 1 Address

Witness 2 Signature


Witness 2 (Typed or Handwritten) Name

Francois Soucy
Witness 2 Address

39 Ellen Rd
Stoneham MA

NO

● Practitioner's Docket No. MPI08-013P1RNM

IN WITNESS WHEREOF, I have hereunto set my hand and seal this _____ day of _____, 2009.

Signature of Inventor Jing Li

Witness 1 Signature

Witness 1 (Typed or Handwritten) Name

Witness 1 Address

Witness 2 Signature

Witness 2 (Typed or Handwritten) Name

Witness 2 Address

(Page 4 of 4)

PATENT
REEL: 023618 FRAME: 0037

12

NO

Practitioner's Docket No. MPI08-013P1RNM

PATENT

For: U.S. and Foreign Rights
For: U.S. Application
By: Inventors

ASSIGNMENT OF INVENTION

WHEREAS,

ASSIGNORS:

Paul E. Fleming19 Eaton Ct., Wellesley, Massachusetts 02481Nationality: United States of AmericaJing Li2223 Ayreshire Drive, Lansdale, Pennsylvania 19446Nationality: China

have co-invented a certain invention entitled:

DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID

for which they have executed an application for a United States patent, which was filed on
September 25, 2009, under U.S. Application No. 12/586,650; and

WHEREAS,

ASSIGNEE:

MILLENNIUM PHARMACEUTICALS, INC.

40 Landsdowne Street

Cambridge, Massachusetts 02139

State of Incorporation: Delaware

is desirous of acquiring ASSIGNORS' entire domestic and foreign right, title, and interest in and under
the invention described in the patent application;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, ASSIGNORS hereby, without reservations, sell, assign and transfer to
ASSIGNEE, its successors, assigns and legal representatives, our entire right, title and interest in and
to the invention in the United States and in every foreign country, and our entire right, title, and
interest in and to the patent application and such other applications (e.g., provisional applications,
non-provisional applications, continuations, continuations-in-part, divisionals, reissues,
reexaminations, National phase applications, including petty patent applications and utility model

PATENT

REEL: 023618 FRAME: 0038

13

Practitioner's Docket No. MPI08-013P1RNM

utility model applications) as may be filed on the invention in the United States or in any foreign country, and the patents, extensions, or derivations thereof, both foreign and domestic, that may issue thereon; said invention, applications, and patents to be held and enjoyed by ASSIGNEE for its own use and behalf and for its successors, assigns and legal representatives, to the full end of the term for which said patents may be granted as fully and entirely as the same would have been held by us had this assignment and sale not been made.

ASSIGNORS hereby authorize the ASSIGNEE to insert in this assignment document the filing date and application number of the application if the date and number are unavailable at the time this document is executed.

ASSIGNORS hereby acknowledge that this assignment, being of our entire right, title and interest in and to said invention, carries with it the right in ASSIGNEE to apply for and obtain from competent authorities in all countries of the world any and all Letters Patent by attorneys and agents of ASSIGNEE's selection and the right to procure the grant of all such Letters Patent to ASSIGNEE for its own name as assignee of the entire right, title and interest therein. ASSIGNORS further acknowledge that this assignment carries with it the right in ASSIGNEE to claim under the Patent Cooperation Treaty, the International Convention and/or other international arrangement for any such application the date of the United States application (or any other application on the invention) to gain priority with respect to other applications.

ASSIGNORS hereby covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

ASSIGNORS further covenant that we will at any time upon request, without further or additional consideration, but at the expense of the ASSIGNEE, execute and deliver such additional assignments and other writings and do such additional acts as the ASSIGNEE may deem necessary or desirable to perfect the ASSIGNEE's enjoyment of this assignment, and render all necessary assistance in making application for and obtaining original, continuation, continuation-in-part, divisional, reissued, reexamined, and National phase patents of the United States or of any and all foreign countries on the invention, and in enforcing any rights or choses in action accruing as a result of such applications or patents, and by executing statements and other affidavits, it being understood that the foregoing covenant and agreement shall bind, and inure to the benefit of, the assigns and legal representative of all parties hereto.

NO

● Practitioner's Docket No. MPI08-013P1RNM

AND, ASSIGNORS do hereby authorize and request the Commissioner of Patents of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said ASSIGNEE, its successors, assigns, and legal representatives.

IN WITNESS WHEREOF, I have hereunto set my hand and seal this _____ day of _____, 2009.

Signature of Inventor Paul E. Fleming

Witness 1 Signature

Witness 1 (Typed or Handwritten) Name

Witness 1 Address

Witness 2 Signature

Witness 2 (Typed or Handwritten) Name

Witness 2 Address


(Page 3 of 4)

PATENT
REEL: 023618 FRAME: 0040


15

Practitioner's Docket No. MPI08-013P1RNM

IN WITNESS WHEREOF, I have hereunto set my hand and seal this 27th day of
October, 2009,



Signature of Inventor Jing Li




Witness 1 Signature

Scott S. Caglia

Witness 1 (Typed or Handwritten) Name

313 Brookwood Dr. Downingtown PA 19335

Witness 1 Address



Witness 2 Signature

KEVIN ALBERTSON

Witness 2 (Typed or Handwritten) Name

6 ACORN DRIVE, BECHTELSTVILLE PA 19505

Witness 2 Address

31

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

In re application of:	Paul E. Fleming, et al.	Confirmation No.:	8289
Application No.:	12/586,650	Group No.:	1614
Filed:	September 25, 2009	Examiner:	Not yet assigned
For:	DERIVATIVES OF 1-AMINO-2-CYCLOBUTYLETHYLBORONIC ACID		


Practitioner's Docket No. MPI08-013P1RNM

PATENT

Certificate of Transmission under 37 CFR 1.8

1-571-273-0140

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

on December 7, 2009

Signature

Paula Swirka

Typed or printed name of person signing Certificate

Submitted herewith:

This Certificate of Transmission under 37 CFR 1.8
Recordation Form Cover Sheet
Assignment

1 page
1 page
8 pages

Total

10 pages
(including this cover sheet)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECORDED: 12/07/2009

PATENT
REEL: 023618 FRAME: 0042

17

-----TRADUCCION OFICIAL No. 11-0529-----

De un documento escrito en INGLES, el cual para su identificación
lleva el sello y firma de la Traductora e Intérprete Oficial, Res.

2755/68 y 01144/97 de Minjusticia.-----

ESTADOS UNIDOS DE AMERICA

A TODOS A QUIENES LOS PRESENTES LLEGAREN:

DEPARTAMENTO DE COMERCIO DE ESTADOS UNIDOS

Oficina De Patentes y Marcas de Estados Unidos

Abril 29, 2011

CERTIFICAMOS POR LA PRESENTE QUE LA ANEXA ES COPIA
AUTENTICA DE LOS ARCHIVOS DE ESTA OFICINA DE UN
DOCUMENTO REGISTRADO EL 7 DE DICIEMBRE DE 2009.

Por autoridad del

SUBSECRETARIO DE COMERCIO PARA PROPIEDAD INTELECTUAL
Y DIRECTOR DE LA OFICINA DE MARCAS Y PATENTES DE ESTADOS
UNIDOS

(fdo) ilegible

T. LAWRENCE

Funcionario de Certificación

(Sello en oblea dorada)

PATENTES UNICAMENTE

Al Director de la Oficina de Patentes y Marcas:



Favor de registrar los documentos adjuntos o las nuevas direcciones siguientes.

Nombre del cedente:

Paul E. Fleming

Jing Li

Nombres adicionales de cedentes? NO

2. Nombre de la parte receptora:

Millenium Pharmaceuticals, Inc.

Dirección interna:-----

Dirección postal: 40 Landsdowne Street

Ciudad: Cambridge, Estado: MA ZIP: 02139

Direcciones o nombres adicionales: NO

3. Naturaleza del traspaso/fecha de otorgamiento:

Fecha otorgamiento: Inventor 1: 10/22/2009 - (2) 10/27/2009

(X) Cesión

4. Solicitud de patente número:

A. Solicitud de patente No. 12/586.650 B. Patente No.-----

Números adicionales adjuntos: NO


5. Nombre y dirección de la parte a quien debe enviarse

correspondencia relacionada con este documento:

Janice M. Klunder

Dirección interna: Millenium Pharmaceuticals, Inc.

Dirección postal: 40 Landsdowne Street



Ciudad: Cambridge , Estado: MA, ZIP 02139

Tel. 617-551-3699

Fax No.: 617-551-8820

Dirección de email: janice.klunder@gmail.com

6. Número total de solicitudes y patentes involucradas: 1

7. Derechos totales (37 CFR 1.21(b) & 3.41) \$40.00

(x) Autorizamos cargarlos a la cuenta de depósito.

8. Cuenta de depósito número: 501668

Nombre de usuario autorizado: Janice M. Klunder

9. Declaración y firma: Según mi conocimiento y creencia la anterior información es verdadera y correcta y toda copia adjunta a la misma es copia fiel del original.

(fdo) ilegible

Fecha: Marzo 14, 2006

Nombre de la persona que firma: Janice M. Klunder, Reg. 41.121

No. total de páginas incluyendo carátula, anexos y documentos: 10

Archivo Practicante No. MPI08-013P1RNM

Para: Derechos en Estados Unidos y el
Exterior

Para: Solicitud de Estados Unidos

Por: Inventores

CESION DE INVENCION



CONSIDERANDO QUE NOSOTROS, Paul E. Fleming, de 19 Eaton Ctr.,
Wellesley, Massachusetts 02481, nacionalidad: Estados Unidos;
Jing Li, 2223 Ayreshire Drive, Lansdale, Pennsylvania 19446
nacionalidad: china, hemos realizado en conjunto cierta invención
titulada:

DERIVADOS DE ácido 1-AMINO-2-CICLOBUTILETILBORÓNICO

Para lo cual hemos firmado una solicitud de patente de Estados
Unidos, que fue presentada el 25 de Septiembre de 2009, bajo la
solicitud de Estados Unidos No. 12/586,650; y

QUE

LA CESIONARIA:

MILLENIUM PHARMACEUTICALS, INC.

40 Landsdowne Street

Cambridge, Massachusetts 02139

Estado de constitución: Delaware

Desea adquirir todo derecho local y del exterior que tengan los
CEDENTES e interés en y sobre la invención descrita en la solicitud de
patente;


En consecuencia, por una consideración positiva y de valor, cuyo
recibo se reconoce por medio del presente, LOS CEDENTES
vendemos, cedemos y traspasamos sin reserva a favor de LA
CESIONARIA, sus sucesores, representantes legales y cesionarios,
todo el derecho, título e interés en y sobre dicha invención en los



Estados Unidos y en cualquier país extranjero, y nuestro pleno derecho, título e interés en y sobre la solicitud de patente y las demás solicitudes (tales como solicitudes provisionales, solicitudes no provisionales, continuación, continuaciones en parte, divisiones, reexpediciones, re-exámenes, solicitudes de fase nacional, incluyendo solicitudes de patentes derivadas y solicitudes de modelos de utilidad) que puedan presentarse sobre la invención en los Estados Unidos o en cualquier país extranjero, y las patentes, extensiones o derivaciones de las mismas, tanto locales como extranjeras que pueden expedirse sobre la misma: dicha invención, solicitudes y patentes serán de propiedad y usufructo del CESIONARIO para su propio uso y representación y para sus sucesores, cesionarios y representantes legales en su totalidad por el término para el cual puedan otorgarse dichas patentes en forma total y plena como si las mismas hubiesen sido otorgadas a nosotros si esta cesión y venta no se hubieran hecho.

LOS CEDENTES por medio del presente autorizan al CESIONARIO a insertar en este documento de cesión la fecha de presentación y número de solicitud si la fecha y número no estuviesen disponibles en el momento de otorgar este documento.

LOS CEDENTES por medio del presente reconocemos que esta cesión, que es de nuestro derecho, título e interés total en y sobre dicha invención conlleva el derecho a favor del CESIONARIO de solicitar y

A handwritten signature in black ink, consisting of stylized, cursive letters that appear to be 'JV' or similar initials.

obtener de las autoridades competentes en todos los países del mundo toda patente por parte de apoderados y agentes seleccionados por el Cesionario para procurar el otorgamiento de toda Patente al CESIONARIO en su propio nombre como cesionario del derecho, título e interés plenos sobre la misma.

LOS CEDENTES reconocemos además que esta cesión conlleva el derecho de la CESIONARIA para reclamar bajo el Tratado de Cooperación de Patentes, la Convención Internacional y/u otro arreglo internacional, cualquier solicitud en la fecha de la solicitud de los Estados Unidos (o cualquier otra solicitud sobre la invención) para obtener prioridad con respecto de otras solicitudes.

LOS CEDENTES por medio garantizan que no han hecho ni harán ni celebrarán ninguna cesión, venta, acuerdo o gravamen que esté en conflicto con esta cesión.

LOS CEDENTES garantizan además que en cualquier momento que se les solicito, sin posterior consideración, pero a costa de la CESIONARIA, otorgarán y entregarán cesiones adicionales u otros escritos y harán los actos adicionales que la CESIONARIA pueda considerar necesarios o deseables para perfeccionar el disfrute de la CESIONARIA de esta cesión y que darán toda la colaboración necesaria para elaborar la solicitud y obtener patentes originales, continuaciones, continuación en parte, divisiones, reexpediciones, re-exámenes y patentes de fase nacional de los Estados Unidos o de



cualesquiera otros países extranjeros sobre la invención y para hacer efectivos los derechos o decisiones en cuanto a obtener resultados de tales solicitudes o patentes, y mediante el otorgamiento de declaraciones u otros actos, quedando entendido que el anterior compromiso y acuerdo será obligatorio y redundará en beneficio de los cesionarios y representantes legales de todas las partes del presente.

Y LOS CEDENTES por medio del presente autorizan y solicitan al Comisionado de Patentes de los Estados Unidos para que emita Patente y se les otorgue sobre dicha solicitud o solicitudes con base en la misma a favor de dicha CESIONARIA, sus sucesores, cesionarios y representantes legales.

EN FE DE LO CUAL, he impuesto aquí mi firma y sello hoy día 22 de Octubre de 2009.

(fdo) ilegible

Firma del Inventor Paul E. Fleming

(fdo) ilegible

Testigo de la firma 1


Philip Wendler

100 Powder Mill Rd, Sudbury, Mass. 01776

(fdo) ilegible

Testigo firma 2

Nombre del testigo 2: Francis Soucy



Dirección testigo 2: 39 Ellen Rd. Stockhom, MA.

Archivo Practicante No. MPI08-013P1RNM

Para: Derechos en Estados Unidos y el

Exterior

Para: Solicitud de Estados Unidos

Por: Inventores

CESION DE INVENCION

CONSIDERANDO QUE NOSOTROS, Paul E. Fleming, de 19 Eaton Ctr.,
Wellesley, Massachusetts 02481, nacionalidad: Estados Unidos;

Jing Li, 2223 Ayreshire Drive, Lansdale, Pennsylvania 19446
nacionalidad: china, hemos realizado en conjunto cierta invención
titulada:

DERIVADOS DE acido 1-AMINO-2-CICLOBUTILETILBORONICO

Para lo cual hemos firmado una solicitud de patente de Estados
Unidos, que fue presenta el 25 de Septiembre de 2009, bajo la
solicitud de Estados Unidos No. 12/586,650; y

QUE


LA CESIONARIA:

MILLENIUM PHARMACEUTICALS, INC.

40 Landsdowne Street

Cambridge, Massachuesetts 02139

Estado de constitución: Delaware

A handwritten signature in black ink, consisting of a stylized 'J' or 'L' followed by a checkmark-like stroke.

Desea adquirir todo derecho local y del exterior que tengan los CEDENTES e interés en y sobre la invención descrita en la solicitud de patente;

En consecuencia, por una consideración positiva y de valor, cuyo recibo se reconoce por medio del presente, LOS CEDENTES vendemos, cedemos y traspasamos sin reserva a favor de LA CESIONARIA, sus sucesores, representantes legales y cesionarios, todo el derecho, título e interés en y sobre dicha invención en los Estados Unidos y en cualquier país extranjero, y nuestro pleno derecho, título e interés en y sobre la solicitud de patente y las demás solicitudes (tales como solicitudes provisionales, solicitudes no provisionales, continuación, continuaciones en parte, divisiones, reexpediciones, re-exámenes, solicitudes de fase nacional, incluyendo solicitudes de patentes derivadas y solicitudes de modelos de utilidad) que puedan presentarse sobre la invención en los Estados Unidos o en cualquier país extranjero, y las patentes, extensiones o derivaciones de las mismas, tanto locales como extranjeras que pueden expedirse sobre la misma: dicha invención, solicitudes y patentes serán de propiedad y usufructo del CESIONARIO para su propio uso y representación y para sus sucesores, cesionarios y representantes legales en su totalidad por el término para el cual puedan otorgarse dichas patentes en forma total y plena como si las



mismas hubiesen sido otorgadas a nosotros si esta cesión y venta no se hubieran hecho.

LOS CEDENTES por medio del presente autorizan al CESIONARIO a insertar en este documento de cesión la fecha de presentación y número de solicitud si la fecha y número no estuviesen disponibles en el momento de otorgar este documento.

LOS CEDENTES por medio del presente reconocemos que esta cesión, que es de nuestro derecho, título e interés total en y sobre dicha invención conlleva el derecho a favor del CESIONARIO de solicitar y obtener de las autoridades competentes en todos los países del mundo toda patente por parte de apoderados y agentes seleccionados por el Cesionario para procurar el otorgamiento de toda Patente al CESIONARIO en su propio nombre como cesionario del derecho, título e interés plenos sobre la misma.

LOS CEDENTES reconocemos además que esta cesión conlleva el derecho de la CESIONARIA para reclamar bajo el Tratado de Cooperación de Patentes, la Convención Internacional y/u otro arreglo internacional, cualquier solicitud en la fecha de la solicitud de los Estados Unidos (o cualquier otra solicitud sobre la invención) para obtener prioridad con respecto de otras solicitudes.

LOS CEDENTES por medio garantizan que no han hecho ni harán ni celebrarán ninguna cesión, venta, acuerdo o gravamen que esté en conflicto con esta cesión.

A handwritten signature in black ink, consisting of a stylized 'J' followed by a checkmark-like flourish.

LOS CEDENTES garantizan además que en cualquier momento que se les solicite, sin posterior consideración, pero a costa de la

CESIONARIA, otorgarán y entregarán cesiones adicionales u otros escritos y harán los actos adicionales que la CESIONARIA pueda considerar necesarios o deseables para perfeccionar el disfrute de la CESIONARIA de esta cesión y que darán toda la colaboración necesaria para elaborar la solicitud y obtener patentes originales, continuaciones, continuación en parte, divisiones, reexpediciones, re-exámenes y patentes de fase nacional de los Estados Unidos o de cualesquiera otros países extranjeros sobre la invención y para hacer efectivos los derechos o decisiones en cuanto a obtener resultados de tales solicitudes o patentes, y mediante el otorgamiento de declaraciones u otros actos, quedando entendido que el anterior compromiso y acuerdo será obligatorio y redundará en beneficio de los cesionarios y representantes legales de todas las partes del presente.

Y LOS CEDENTES por medio del presente autorizan y solicitan al Comisionado de Patentes de los Estados Unidos para que emita Patente y se les otorgue sobre dicha solicitud o solicitudes con base en la misma a favor de dicha CESIONARIA, sus sucesores, cesionarios y representantes legales.

EN FE DE LO CUAL, he impuesto aquí mi firma y sello hoy día 27 de Octubre de 2009.

A handwritten signature in black ink, consisting of a stylized, cursive script that appears to be the initials 'JH' followed by a long, sweeping horizontal stroke.

(fdo) ilegible

Firma del Inventor Jing Li

(fdo) ilegible

Testigo de la firma 1

Scott S. Ceglia

313 Brookwood Dr., Downingtown PA 19335

(fdo) ilegible

Testigo firma 2

Nombre del testigo 2: Kevin Albertson

6 Acorn Drive, Bechtelsville, PA 19505


APOSTILLA

(Convención de La Haya de Octubre 5, 1961)

1. País: Estados Unidos de América
2. Este documento público ha sido firmado por: T. Lawrence
3. Actuando en el carácter de Funcionario de Certificación
4. lleva el sello de: Oficina de Patentes y Marcas de Estados Unidos

CERTIFICADO

5. EN Washington D.C.
6. El día 18 de Mayo de 2011
7. por: el Funcionario de Autenticación Asistente, Departamento de Estado de Estados Unidos
8. No. 11030719-1
9. Sello: (en relieve)



MARIA DORA DUQUE DE BERNAL
TRADUCTORA E INTERPRETE OFICIAL
R.S 02755/68 Y 01144/97 - MINJUSTICIA
RE. DE COLOMBIA